MediciNova posts Phase 2 MN-001 topline data showing early triglyceride reduction in NAFLD patients with type 2 diabetes

Bitget2026/09/28 10:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

MediciNova disclosed topline Phase 2 results for MN-001 in NAFLD with hypertriglyceridemia tied to type 2 diabetes.
Trial met an early triglyceride-lowering signal versus placebo, while the longer-term comparison did not reach statistical significance.
Data showed statistically significant improvements in HDL-related measures; liver fat and body weight trended better without clear significance.
Safety profile was generally favorable, with no drug-related serious adverse events reported.
Management signaled the program needs a larger follow-on study, with design work underway on population, endpoints, and sample size.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediciNova Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280600PRIMZONEFULLFEED9834681) on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

MediciNova posts Phase 2 MN-001 topline data showing early triglyceride reduction in NAFLD patients with type 2 diabetes

You may also like

Crypto prices